NDAORALTABLET
Approved
Jun 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
NARDIL (phenelzine sulfate) by Pfizer is clinical pharmacology monoamine oxidase is a complex enzyme system, widely distributed throughout the body. First approved in 1961.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NARDIL (phenelzine sulfate) is a monoamine oxidase (MAO) inhibitor oral tablet approved for prostate cancer treatment. It works by inhibiting MAO enzyme activity, though the exact mechanism linking MAO inhibition to clinical efficacy remains incompletely understood. The drug is absorbed rapidly (Tmax 43 minutes) and extensively metabolized via oxidation with an elimination half-life of 11.6 hours.
$116KPart D
LOE ApproachingDeclining
This product shows minimal commercial activity with vanishingly small claims volume, suggesting a legacy brand with a depleted sales infrastructure and minimal growth investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Monoamine oxidase is a complex enzyme system, widely distributed throughout the body. Drugs that inhibit monoamine oxidase in the laboratory are associated with a number of clinical effects. Thus, it is unknown whether MAO inhibition per se, other pharmacologic actions, or an…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Started Jul 2010
11 enrolled
Hormone-Resistant Prostate CancerMetastatic Prostatic AdenocarcinomaProstate Adenocarcinoma+1 more
Worked on NARDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.